Metabolic
Peptides
Compound profile

Retatrutide: Triple GIP/GLP-1/Glucagon Agonist

A triple-receptor agonist (GIP/GLP-1/glucagon) currently in Phase 2/3 trials for obesity and metabolic disease.

On this page

What it is

Retatrutide is a synthetic peptide combining GIP, GLP-1, and glucagon receptor agonism in a single molecule. Developed by Eli Lilly.

Evidence snapshot

Category: Metabolic. Status: Human Trials. See the references section below for the underlying primary sources.

Mechanism

Activates GIP and GLP-1 receptors (reducing appetite) and the glucagon receptor (increasing energy expenditure). The combination is hypothesised to produce greater weight loss than dual-agonists.

Key research findings

Phase 2 trial data in obesity showed dose-dependent weight loss up to ~24% over 48 weeks — among the largest reported in any obesity pharmacotherapy development program.

Limits of the evidence

Phase 3 data not yet published. Long-term safety of chronic glucagon agonism requires longer follow-up. Adverse event profile includes GI effects.

Continue reading

Tissue Repair

BPC-157

Synthetic pentadecapeptide derived from a gastric juice protein, studied across hundreds of preclinical reports for tissue regeneration and cytoprotection.
Read Guid
Tissue Repair

TB-500 (Thymosin Beta-4 fragment)

Synthetic fragment of Thymosin Beta-4, a 43-amino-acid peptide investigated for its role in actin regulation, cell migration, and wound healing.
Read Guid
Peptide Protocols

BPC-157 + TB-500

Combined tissue-repair peptides with complementary mechanisms — the synergy hypothesis examined critically against the available preclinical record.
Read Guid
Growth Hormone · Research

Ipamorelin

Selective pentapeptide agonist of the growth hormone secretagogue receptor (GHSR-1a) studied for targeted GH release with minimal effect on cortisol, ACTH and prolactin.
Read Guid